Neurol. praxi. 2017;18(1):49-53 | DOI: 10.36290/neu.2018.065
Aubagio (teriflunomide) as one of the treatment options in men with multiple sclerosis
- Neurologická klinika FN a LF UP Olomouc
Aubagio is one of the treatment options in multiple sclerosis. The active substance is teriflunomide that inhibits the mitochondrial
enzyme dihydroorotate dehydrogenase. It is the only first-line oral medication and is taken at a dose of 14 mg once a day. It is a
suitable drug of choice, among other things, in young men actively engaged in sport and work, particularly due to the fact of it
being an oral medication with a very good safety profile. Three case reports are presented with the aim to document the effect
of teriflunomide. All the patients are young men who have been on the treatment for several years.
Keywords: eriflunomide, Aubagio, multiple sclerosis, clinically isolated syndrome
Received: October 21, 2018; Accepted: October 29, 2018; Published: March 1, 2017 Show citation
References
- Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L. Oral teriflunomide for patients with relapsimg multiple sclerosis (TOWER): a randomiized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 247-256.
Go to original source... - Davenport L, Czich A, Turpault S. Germany Teriflunomide: No Effects on Sperm DNA. 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2-5 October 2013, Copenhagen, Denmark.
- Dufek M. Aubagio v léčbě pacientů s roztroušenou sklerózou - klinické zkušenosti po roce používání v České republice; XIII. sympozium praktické neurologie; Brno; 2. 6. 2016.
- Dufek M. Roztroušená skleróza - EDSS (expanded disability status scale), tzv. Kurtzkeho škála. Neurol. praxi. 2011: 12.
- Kantorová E. Teriflunomid v praxi - vlastné skúsenosti; 29. slovenský a český neurologický zjazd; Košice 21.-24. 10. 2015.
- Kappos L. Teriflunomide; impact on disability progression and MRI activity; L. Kappos Satellite Symposium: Preserving brain and function; evolution from T and B cell pathophysiology to treatment; ECTRIMS Barcelona; 8. 10. 2015.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov; 33(11): 1444-1452. Go to original source...
Go to PubMed... - Mareš J. Biologická léčba DMD 1. linie - mezinárodní doporučení vs. úhradová vyhláška; 11. Olomoucké neuroimunolgické sympozium s mezinárodí účastí; Olomouc; 15.-16. 10. 2015.
- Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P, Wang L, D'Castro L, Comi G, Freedman MS. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler. 2012 Nov; 18(11): 1625-1632. Go to original source... Go to PubMed...
- Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomiized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 977-986. Go to original source...
- Reder AT. The foundation of MS and approach to treatment: the role of T and B cells; Satellite Symposium: Preserving brain and function; evolution from T and B cell pathophysiology to treatment; ECTRIMS Barcelona; 8. 10. 2015.